HD is an autosomal dominant genetic disorder with a global prevalence of approximately 2.7/100,000 and an incidence rate of about 0.38/100,000 annually. The prevalence is around 5.7/100,000 in Europe, North America, and Australia, and about 0.4/100,000 in Asia. The causative gene for HD is the huntingtin gene (HTT), which encodes a large protein with over 3,000 amino acids. An abnormal expansion of CAG trinucleotide repeats in the first exon of HTT leads to misfolding of the huntingtin protein (mHTT). This mutated protein accumulates in the brain, ultimately causing neurological dysfunction and degeneration. Targeting the suppression of mHTT expression may be key to treating Huntington’s disease.
On May 17, 2024, Professors Xiaojiang Li and Su Yang from Jinan University published their latest research findings in the journal Science Advances. Their study reported previously unidentified pathogenic mechanisms of HTT and discovered a primate-specific E3 ubiquitin ligase, TRIM37. TRIM37 promotes the ubiquitination and degradation of mutant HTT (mHTT) and regulates its aggregation in the brains of mice and monkeys. Therefore, TRIM37 protein can be considered a potential therapeutic target for Huntington’s disease by modulating mHTT expression. PackGene provided AAV packaging services for this study.
https://pubmed.ncbi.nlm.nih.gov/38758800/
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
More Articles
Investigating Opioid Peptides: AAV Vector-Delivered Fluorescence Sensors for Studying Opioid Dynamics
Neuropeptides (NPs) play a crucial role in the nervous system, influencing neural activity, brain states, and blood flow. However, the complexity of these molecules, particularly opioid peptides, has presented significant challenges in research due to the lack of...
Exploring Liver Regeneration: A Spatiotemporal Atlas of Mouse Liver
Understanding liver regeneration is crucial for advancements in regenerative medicine and disease research. In a groundbreaking study, researchers combined Stereo-seq (spatiotemporal enhanced resolution omics-sequencing) with single-cell RNA sequencing to create a...
Overview of Key AAV Analytical Testing for Gene Therapy Development
In the development of AAV-based gene therapies, ensuring the quality and efficacy of the viral vectors is paramount. Several critical tests are employed to assess various aspects of AAV vectors, each addressing specific factors that impact the safety and effectiveness...
Advancing Miniature Gene Editing: High-Efficiency IscB Variants Enable In Vivo Therapeutic Potential
Over the past decade, gene editing technologies, particularly CRISPR/Cas9 and its derivatives, have rapidly advanced, enabling more precise and efficient genetic modifications. This progress offers new possibilities for better understanding life processes and...
Related Services
AAV Packaging Services
READ MORE
AAV Packaging Service (NHP)
READ MORE
AAV Packaging Service (HT)
READ MORE
